Nuvalent, Inc. (NUVL)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$123.960.00%
Close 2026-07-16 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put NUVL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
The reason to own it still holds.
View ThesisRelatively steady — typically moves about 1% a day.
View RiskNot enough reads yet
NUVL’s case rests on steady financial performance in a supportive sector, despite recent results below peers. The company was unprofitable over the past year, so earnings quality remains unassessed. No earnings release is on record, leaving growth and the latest result unverified. Valuation multiples and a priced-in expectations read are unavailable. Our model puts the next-quarter miss probability near 33%. The thesis remains intact, though its support is hard to verify. This read is provisional.
Trailing returns as of 2026-07-16. NUVL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering NUVL (as of Jul 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare NUVL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NUVL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put NUVL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Entry into Merger Agreement with GSK
Acquisition confirms growth strategy with GSK.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-16. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Entry into Merger Agreement with GSK
Acquisition aligns with growth in oncology.
Advances: Entry into Merger Agreement with GSK
GSK's investment boosts oncology strategy.